GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.48
+7.25%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.40
From 52W high−97.66%
Volume42497.00
Market cap$3.24M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.40
From 52W high
−97.66%
Volume
42497.00
Market cap
$3.24M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
P/E (TTM)
—
RSI (14)
35.4
MomentumView details →
1D Return
+7.25%
YTD Return
−79.09%
SummaryUpdated Jun 1, 2026
GRI Bio, Inc. (NASDAQ:GRI) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in La Jolla, California. Originally established as Glycoregimmune, Inc., the company went public in February 2021 and focuses on developing novel therapeutic treatments for inflammatory, fibrotic, and autoimmune diseases. As a clinical-stage biotechnology firm, GRI Bio operates without generating product revenue, instead relying on research and development activities to advance its pipeline of experimental drug candidates through various phases of clinical trials.
Similar companies
Latest newsMore news →
GRI Bio announced that three abstracts and an oral presentation highlighting data from its Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society Congress in Barcelona, Spain.57d agoThe U.S. Food and Drug Administration granted Orphan Drug Designation to GRI Bio's drug GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.124d ago